Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 2, 1997, Pages 194-202

  Sironi, Anna Maria ^b   Vichi, Silvia ^b   Gastaldelli, Amalia ^b   Pecori, Neda ^b   Anichini, Roberto ^b   Foot, Elizabeth ^b   Seghieri, Giuseppe ^b   Ferrannini, Ele ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TROGLITAZONE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHROMANS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; POTASSIUM; RISK FACTORS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0030868981     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90068-0     Document Type: Article

References (22)

1. King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993;16:157-77.
2. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 1992;15:318-68.
3. Olefsky JM. Diabetes mellitus (type II): etiology and pathogenesis. In: De Groot LJ, Besser M, Jameson JL, Loriaux DL, Marshall JC, Odell WD, et al., editors. Endocrinology. 3rd ed. Philadelphia: WB Saunders, 1995:1436-63.
4. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988:318:1231-9.
5. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991:14:173-94.
6. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045 (studies in KK and ob/ob mice and Zucker fatty rats). Diabetes 1988:37:1549-58.
7. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990: 39:1056-62.
8. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991:14:1083-6.
9. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992:15: 193-203.
10. Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, et al. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 1994:11:685-91.
11. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994:331:1188-93.
12. Wolfe RR. Radioactive and stable isotope tracers in biomedicine: principles and practice of kinetic analysis. New York: Wiley, 1992.
13. Shen SW, Reaven GM, Farquar JW. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 1970:49:2151-60.
14. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996:19: 151-6.
15. Kumar S, Boulton AJM, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, et al. Troglitazone, an insulin action-enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996:39:701-9.
16. Fujiwara T, Okuno A, Yoshioka S, Horikoshi H. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 1995:44:486-90.
17. Olefsky JM. Pathogenesis of insulin resistance and hyperglycemia in non-insulin-dependent diabetes mellitus. Am J Med 1985:79(suppl 3B):1-7.
18. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and non-insulin-dependent diabetic subjects. J Clin Invest 1984:74:1238-46.
19. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989:38:387-95.
20. Stuart CA, Shangraw RE, Prince MJ, Peters EJ, Wolfe RR. Bed-rest-induced insulin resistance occurs primarily in muscle. Metabolism 1988:37:802-6.
21. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988:37:1595-607.
22. Levin K, Thye-Ronn P, Foot E, Beck-Nielsen H. Metabolic effects of troglitazone (an insulin action-enhancer) in NIDDM-patients [abstract]. Diabetologia 1995:38:A200.